BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
12/2/2015 12:19:00 PM | Browse: 476 | Download: 399
Publication Name World Journal of Hepatology
Manuscript ID 11646
Country of Manuscript Source Spain
Received
2014-05-29 09:28
Peer-Review Started
2014-05-29 21:22
To Make the First Decision
2014-06-27 11:52
Return for Revision
2014-06-27 19:00
Revised
2014-07-14 00:00
Second Decision
2014-08-31 16:55
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief
2014-08-31 17:10
Articles in Press
2014-08-31 17:10
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript
2014-10-27 15:03
Publish the Manuscript Online
2014-11-05 09:07
ISSN 1948-5182 (online)
Open Access
Copyright
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Specialty Gastroenterology and Hepatology
Manuscript Type Review
Article Title Targeting the insulin-like growth factor pathway in hepatocellular carcinoma
Manuscript Source Invited Manuscript
All Author List Mónica Enguita-Germán and Puri Fortes
Funding Agency and Grant Number
Funding Agency Grant Number
Ministerio de Ciencia e Innovacion BIO2009/09295
Ministerio de Ciencia e Innovacion SAF2012-40003
FEDER funding
RNAREG CSD2009-00080
Ministryof Science and Innovation under the programme CONSOLIDER INGENIO 2010
Corresponding author Dr. Puri Fortes, Department of Hepatology and Gene Therapy, Center for Applied Medical Research, Pio XII, 55, 31008 Pamplona, Spain. pfortes@unav.es
Keywords Hepatocellular carcinoma; Insulin; Insulin-like growth factor; Insulin-like growth factor receptor; Therapy; Tyrosine kinase inhibitor; Antibody therapy
Core Tip It is mandatory to develop alternative therapies for the successful treatment of hepatocellular carcinoma (HCC). One of the key drivers of hepatocarcinogenesis is the insulin-like growth factor (IGF) system. Therefore, several inhibitors of this pathway have been developed and their therapeutic potential is being tested in patients with HCC. However, recent studies suggest that IGF-Ⅱ, a member of the pathway, may be more relevant for hepatocarcinogenesis than its close homologue IGF-Ⅰ. The purpose of this review is to summarize these facts within a detailed description of the IGF axis and the alterations of the pathway that lead to HCC. The strategies designed to target the IGF-Ⅰ?signaling pathway for HCC treatment are also reviewed.
Publish Date 2014-11-05 09:07
Citation Enguita-Germán M, Fortes P. Targeting the insulin-like growth factor pathway in hepatocellular carcinoma. World J Hepatol 2014; 6(10): 716-737
Url http://www.wjgnet.com/1948-5182/full/v6/i10/716.htm
DOI http://dx.doi.org/10.4254/wjh.v6.i10.716
Full Article (PDF) WJH-6-716.pdf
Full Article (Word) WJH-6-716.doc
Manuscript File 11646-Review.doc
Answering Reviewers 11646-Answering reviewers.pdf
Copyright License Agreement 11646-Copyright assignment.pdf
Peer-review Report 11646-Peer review(s).pdf
Scientific Misconduct Check 11646-CrossCheck.jpg
Scientific Editor Work List 11646-Scientific editor work list.pdf